New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis–Related Kidney Disease

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 7, 2017, Pages 972-985

  Musso, Giovanni ^a   De Michieli, Franco ^a   Bongiovanni, Daria ^a   Parente, Renato ^a   Framarin, Luciana ^a   Leone, Nicola ^a   Berrutti, Mara ^a   Gambino, Roberto ^b   Cassader, Maurizio ^b   Cohney, Solomon ^c   Paschetta, Elena ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CKD; eGFR; Fibrosis; NASH; Renal Function

Indexed keywords

2 (2 CHLOROPHENYL) 4 [3 (DIMETHYLAMINO)PHENYL] 5 METHYL 1H PYRAZOLO[4,3 C]PYRIDINE 3,6(2H,5H) DIONE; ALEGLITAZAR; ALISKIREN; APOPTOSIS SIGNAL REGULATING KINASE 1; CHAPERONIN 60; DIMINAZENE; ELAFIBRANOR; FARNESOID X RECEPTOR; FIBRIC ACID DERIVATIVE; HEAT SHOCK PROTEIN 100; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INT 131; MERCAPTAMINE; MICRORNA 103; MICRORNA 107; MITOGLITAZONE; OBETICHOLIC ACID; OLIGONUCLEOTIDE; PEMAFIBRATE; PENTOXYFILLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHODIESTERASE INHIBITOR; PIOGLITAZONE; SELADELPAR; SOLITHROMYCIN; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ARTICLE; CELL STRESS; CHRONIC KIDNEY FAILURE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EPIGENETICS; HEAT STRESS; HUMAN; KIDNEY INJURY; LIVER FIBROSIS; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG DEVELOPMENT; FIBROSIS; INFLAMMATION; KIDNEY DISEASE; PRECLINICAL STUDY; TRENDS;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FIBROSIS; HUMANS; INFLAMMATION; KIDNEY DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85020658831     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.08.002     Document Type: Article

References (133)

1. Musso, G., Gambino, R., Cassader, M., et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 (2011), 617–649.
2. Musso, G., Gambino, R., Tabibian, J.H., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med, 11, 2014, e1001680.
3. Stepanova, M., Se Avila, L., Birerdinc, A., et al. In female patients with NAFLD presence of type 2 diabetes and chronic kidney disease are independently associated with the risk of mortality. Hepatology 62 (2015), 1282–1283A.
4. Singal, A.K., Hasanin, M., Kaif, M., et al. Nonalcoholic steatohepatitis is the most rapidly growing indication for simultaneous liver kidney transplantation in the United States. Transplantation 100 (2016), 607–612.
5. Musso, G., Cassader, M., Rosina, F., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55 (2012), 885–904.
6. Palmer, S.C., Mavridis, D., Navarese, E., et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385 (2015), 2047–2056.
7. Lee, K.C., Hsieh, Y.C., Yang, Y.Y., et al. Aliskiren reduces hepatic steatosis and epididymal fat mass and increases skeletal muscle insulin sensitivity in high-fat diet-fed mice. Sci Rep, 6, 2016, 18899.
8. Lee, K.C., Chan, C.C., Yang, Y.Y., et al. Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. PLoS One, 8, 2013, e77817.
9. Renke, M., Lizakowski, S., Tylicki, L., et al. Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-placebo controlled, randomized, cross-over study. Adv Med Sci 59 (2014), 256–260.
10. Santos, S.H., Andrade, J.M., Fernandes, L.R., et al. Oral angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-κB in rats fed with high-fat diet. Peptides 46 (2013), 47–52.
11. Velkoska, E., Patel, S.K., Griggs, K., et al. Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy. PLoS One, 10, 2015, e0118758.
12. Trojanowicz, B., Ulrich, C., Kohler, F., et al. Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease. Nephrol Dial Transplant, 2016 Epub ahead of print.
13. Mak, K.Y., Chin, R., Cunningham, S.C., et al. ACE2 therapy using adeno-associated viral vector inhibits liver fibrosis in mice. Mol Ther 23 (2015), 1434–1443.
14. de Macêdo, S.M., Guimarares, T.A., Andrade, J.M., et al. Angiotensin converting enzyme 2 activator DIZE modulates metabolic profile in mice decreasing lipogenesis. Protein Pept Lett 22 (2015), 332–340.
15. Tang, A., Li, C., Zou, N., et al. Angiotensin-(1–7) improves non-alcoholic steatohepatitis via an adiponectin-independent mechanism. Hepatol Res, 2016 Epub ahead of print.
16. Perez-Gomez, M.V., Sanchez-Niño, M.D., Sanz, A.B., et al. Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opin Investig Drugs 13 (2016), 1–14.
17. Du, J., Ma, Y.Y., Yu, C.H., et al. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 20 (2014), 569–577.
18. Navarro-Gonzalez, J.F., Mora-Fernandez, C., Muros de Fuentes, F.M., et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol 26 (2015), 220–229.
19. Leporini, C., Pisano, A., Russo, E., et al. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta-analysis. Pharmacol Res 107 (2016), 315–332.
20. Dohil, R., Meyer, L., Schmeltzer, S., et al. The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects. J Pediatr 161 (2012), 639–645.
21. Okamura, D.M., Bahrami, N.M., Ren, S., et al. Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD. J Am Soc Nephrol 25 (2014), 43–54.
22. Schwimmer, J.B., Lavine, J.E., Wilson, L.A., et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology 151 (2016), 1125–1138.
23. Kang, H.M., Ahn, S.H., Choi, P., et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 21 (2015), 37–46.
24. Xu, Y., Huang, J., Xin, W., et al. Lipid accumulation is ahead of epithelial-to-mesenchymal transition and therapeutic intervention by acetyl-CoA carboxylase 2 silence in diabetic nephropathy. Metabolism 63 (2014), 716–726.
25. Herman-Edelstein, M., Scherzer, P., Tobar, A., et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res 55 (2014), 561–572.
26. Musso, G., Cassader, M., Gambino, R., Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov 15 (2016), 249–274.
27. Musso, G., Cassader, M., Cohney, S., et al. Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care, 2016 Epub ahead of print.
28. Ting, R.D., Keech, A.C., Drury, P.L., et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 35 (2012), 218–225.
29. Li, X., Li, J., Lu, X., et al. Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model. Int J Mol Med 36 (2015), 767–775.
30. Staels, B., Rubenstrunk, A., Noel, B., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58 (2013), 1941–1952.
31. Collino, M., Benetti, E., Rogazzo, M., et al. Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol 85 (2013), 257–264.
32. Lee, E.Y., Kim, G.T., Hyun, M., et al. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. Nephrol Dial Transplant 27 (2012), 4069–4079.
33. Bays, H.E., MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 96 (2011), 2889–2897.
34. Sanyal, A.J., Harrison, S.A., Francque, S.M., et al. The hepatic and extrahepatic profile of resolution of steatohepatitis induced by GFT-505. Hepatology, 62, 2015, 1252A.
35. Sarafidis, P.A., Stafylas, P.C., Georgianos, P.I., et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 55 (2010), 835–847.
36. DePaoli, A.M., Higgins, L.S., Henry, R.R., et al. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?. Diabetes Care 37 (2014), 1918–1923.
37. Colca, J.R., VanderLugt, J.T., Adams, W.J., et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin Pharmacol Ther 93 (2013), 352–359.
38. McCommis, K.S., McDonald, W.G., Colca, J.R., et al. Modulating mitochondrial pyruvate carrier activity decreases hepatic fibrosis in a mouse model of NASH. Diabetes, 65, 2016, A36.
39. DeWitt, S.H., Jacques, V., Van der Ploeg, L.H., VL DRX-065, the stabilized R-enantiomer of pioglitazone is without PPARg agonist activity and exhibits the beneficial in vivo pharmacodynamic effects for the treatment of NASH. Hepatology 62 (2015), 281A–282A.
40. Mukul R. Saroglitazar shows therapeutic benefits in mouse model of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) (abstract 1957-P). American Diabetes Association 75th Scientific Sessions, June 5–9, 2015, Boston, MA.
41. Banshi D. To assess the effect of 4mg saroglitazar on patients of diabetes dyslipidemia with nonalcoholic fatty liver disease for 24 weeks at diabetes care CentreView session detail (abstract 712-P). American Diabetes Association 75th Scientific Sessions, June 5–9, 2015, Boston, MA.
42. Ruilope, L., Hanefeld, M., Lincoff, A.M., et al. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a phase IIb, randomized study. BMC Nephrol, 15, 2014, 180.
43. Gai, Z., Gui, T., Hiller, C., et al. Farnesoid X receptor protects against kidney injury in uninephrectomized obese mice. J Biol Chem 291 (2016), 2397–2411.
44. Wang, X.X., The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol 297 (2009), F1587–F1596.
45. Li, J., Wilson, A., Gao, X., et al. Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine. J Pharmacol Exp Ther 331 (2009), 234–243.
46. Neuschwander-Tetri, B., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
47. Musso, G., Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost. Hepatology 61 (2015), 2104–2106.
48. Sekar, D., Venugopal, B., Sekar, P., et al. Role of microRNA 21 in diabetes and associated/related diseases. Gene 582 (2016), 14–18.
49. Trajkovski, M., Hausser, J., Soutschek, J., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474 (2011), 649–653.
50. Bhatia, H., Pattnaik, B.R., Datta, M., Inhibition of mitochondrial β-oxidation by miR-107 promotes hepatic lipid accumulation and impairs glucose tolerance in vivo. Int J Obes (Lond) 40 (2016), 861–869.
51. Takeuchi-Yorimoto, A., Yamaura, Y., Kanki, M., et al. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. Toxicol Lett 258 (2016), 159–167.
52. Dattaroy, D., Pourhoseini, S., Das, S., et al. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 308 (2015), G298–G312.
53. Chau, B.N., Xin, C., Hartner, J., et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med, 4, 2012, 121ra18.
54. Bao, H., Hu, S., Zhang, C., et al. Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy. Biochem Biophys Res Commun 444 (2014), 455–460.
55. Wu, H., Ng, R., Chen, X., et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut, 2015 Epub ahead of print.
56. Song, N., Ma, X., Li, H., et al. microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes. Urol Oncol, 33, 2015, 205 e1–11.
57. Sreedharan, R., Van Why, S.K., Heat shock proteins in the kidney. Pediatr Nephrol 31 (2016), 1561–1570.
58. Wheeler, M.C., Gekakis, N., Hsp90 modulates PPARγ activity in a mouse model of nonalcoholic fatty liver disease. J Lipid Res 55 (2014), 1702–1710.
59. Lazaro, I., Oguiza, A., Recio, C., et al. Targeting HSP90 ameliorates nephropathy and atherosclerosis through suppression of NF-κB and STAT signaling pathways in diabetic mice. Diabetes 64 (2015), 3600–3613.
60. Noh, H., Kim, H.J., Yu, M.R., et al. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-β type II receptor. Lab Invest 92 (2012), 1583–1596.
61. Abu-Elsaad, N.M., Serrya, M.S., El-Karef, A.M., et al. The heat shock protein 90 inhibitor, 17-AAG, attenuates thioacetamide induced liver fibrosis in mice. Pharmacol Rep 68 (2016), 275–282.
62. Xia, Z., Abe, K., Furusu, A., et al. Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47. Am J Nephrol 28 (2008), 34–46.
63. Paik, Y.H., Kim, J., Aoyama, T., et al. Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal 20 (2014), 2854–2872.
64. Gorin, Y., Wauquier, F., Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease. Mol Cells 38 (2015), 285–296.
65. Jha, J.C., Gray, S.P., Barit, D., et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 25 (2014), 1237–1254.
66. Lan, T., Kisseleva, T., Brenner, D.A., Deficiency of NOX1 or NOX4 prevents liver inflammation and fibrosis in mice through inhibition of hepatic stellate cell activation. PLoS One, 10, 2015, e0129743.
67. Aoyama, T., Paik, Y.H., Watanabe, S., et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56 (2012), 2316–2327.
68. Schroder, K., Zhang, M., Benkhoff, S., et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 110 (2012), 1217–1225.
69. Kawarazaki, Y., Ichijo, H., Naguro, I., Apoptosis signal-regulating kinase 1 as a therapeutic target. Expert Opin Ther Targets 18 (2014), 651–664.
70. Yamamoto, E., Dong, Y.F., Kataoka, K., et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 52 (2008), 573–580.
71. Ma, F.Y., Tesch, G.H., Nikolic-Paterson, D.J., ASK1/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney. Am J Physiol Renal Physiol 307 (2014), F1263–F1273.
72. Tesch, G.H., Ma, F.Y., Han, Y., et al. ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-deficient mice. Diabetes 64 (2015), 3903–3913.
73. Liu, Z., Dou, W., Ni, Z., et al. Deletion of Nrf2 leads to hepatic insulin resistance via the activation of NF-κB in mice fed a high-fat diet. Mol Med Rep 14 (2016), 1323–1331.
74. Shimozono, R., Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol 84 (2013), 62–70.
75. Choi, B.H., Kang, K.S., Kwak, M.K., Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules 19 (2014), 12727–12759.
76. Hutton, H.L., Ooi, J.D., Holdsworth, S.R., et al. The NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology (Carlton) 21 (2016), 736–744.
77. Mridha, A.R., Wree, A., Avril, A., et al. Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH. Hepatology 62 (2015), 235–236A.
78. Mora, E., Guglielmotti, A., Biondi, G., et al. Bindarit: an anti-inflammatory small molecule that modulates the NFkappaB pathway. Cell Cycle 11 (2012), 159–169.
79. Sharifnia, T., Antoun, J., Verriere, T.G., et al. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol 309 (2015), G270–G278.
80. Fang, Q., Deng, L., Wang, L., et al. Inhibition of mitogen-activated protein kinases/nuclear factor κB-dependent inflammation by a novel chalcone protects the kidney from high fat diet-induced injuries in mice. J Pharmacol Exp Ther 355 (2015), 235–246.
81. Furfaro, L.L., Spiller, O.B., Keelan, J.A., et al. In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin. Int J Antimicrob Agents 46 (2015), 319–324.
82. Fernandes, P., Oldach, D., Pierre, M., et al. Mechanism of action of the anti-NASH effects of solithromycin in a predictive NASH HCC mouse model. Hepatology, 62, 2015, 1301A.
83. Kobayashi, Y., Wada, H., Rossios, C., et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther 345 (2013), 76–84.
84. Baeck, C., Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology 59 (2014), 1060–1072.
85. Wu, H.J., Yiu, W.H., Li, R.X., et al. Mesenchymal stem cells modulate albumin-induced renal tubular inflammation and fibrosis. PLoS One, 9, 2014, e90883.
86. Lefebvre, E., Moyle, G., Reshef, R., et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One, 11, 2016, e0158156.
87. de Zeeuw, D., Bekker, P., Henkel, E., et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 3 (2015), 687–696.
88. Hammerich, L., Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 59 (2014), 630–642.
89. Ferolla, S.M., Couto, C.A., Armiliato, G.N., et al. Improvement in hepatic steatosis in NASH in response to synbiotic supplementation. Hepatology, 62, 2015, 1280A.
90. Rossi, M., SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrol, 15, 2014, 106.
91. Mizrahi, M., Shabat, Y., Ben Ya'acov, A., et al. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res 5 (2012), 141–150.
92. Mudaliar, H., Pollock, C., Panchapakesan, U., Role of Toll-like receptors in diabetic nephropathy. Clin Sci (Lond) 126 (2014), 685–694.
93. Oregui, A., Culberson, C., Norris, E., et al. A TLR4 antagonist decreases hepatic inflammation in response to endotoxin in fatty livers. J Hepatol, 22, 2015, 166A.
94. Armstrong, M.J., Hull, D., Guo, K., et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatophepatitis. J Hepatol 64 (2016), 399–440.
95. Cui, J., Philo, L., Nguyen, P., et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 65 (2016), 369–376.
96. Gögebakan, Ö., Osterhoff, M.A., Schüler, R., GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. Diabetologia 58 (2015), 1759–1768.
97. Nasteska, D., Harada, N., Suzuki, K., Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 63 (2014), 2332–2343.
98. Imamura, S., Hirai, K., Hirai, A., The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med 231 (2013), 57–61.
99. Groop, P.H., Cooper, M.E., Perkovic, V., et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36 (2013), 3460–3468.
100. Zhang, F., Yu, L., Lin, X., et al. Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases. Mol Endocrinol 29 (2015), 1400–1413.
101. Huang, X., Yang, C., Luo, Y., et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 56 (2007), 2501–2510.
102. Tomlinson, E., Fu, L., John, L., Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143 (2002), 1741–1747.
103. Eren, F., Kurt, R., Ermis, F., et al. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 45 (2012), 655–658.
104. Li, M., Qureshi, A.R., Ellis, E., et al. Impaired postprandial fibroblast growth factor (FGF)-19 response in patients with stage 5 chronic kidney diseases is ameliorated following antioxidative therapy. Nephrol Dial Transplant 28 (2013), iv212–iv219.
105. Zhou, M., Wang, X., Phung, V., et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res 74 (2014), 3306–3316.
106. Weston, C.J., Adams, D.H., Hepatic consequences of vascular adhesion protein-1 expression. J Neural Transm 118 (2011), 1055–1064.
107. Weston, C.J., Shepherd, E.L., Claridge, L.C., et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest 125 (2015), 501–520.
108. Wong, M.Y., Saad, S., Zhang, J., et al. Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model. Am J Physiol Renal Physiol 307 (2014), F908–F916.
109. Katagiri, D., Hamasaki, Y., Doi, K., et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Kidney Int 89 (2016), 374–385.
110. Iacobini, C., Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol 54 (2011), 975–983.
111. DePeralta, D.K., Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 59 (2014), 1577–1590.
112. Kikuchi, Y., Kobayashi, S., Hemmi, N., et al. Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant 19 (2004), 602–607.
113. Calvier, L., Martinez-Martinez, E., Miana, M., et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 3 (2015), 59–67.
114. O'Seaghdha, C.M., Hwang, S.J., Ho, J.E., et al. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 24 (2013), 1470–1477.
115. Drechsler, C., Delgado, G., Wanner, C., et al. Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies. J Am Soc Nephrol 26 (2015), 2213–2221.
116. Frenay, A.R., Yu, L., van der Velde, A.R., et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol 308 (2015), F500–F509.
117. Traber, P.G., Eliezer Zomer, E., Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One, 8, 2013, e83481.
118. Traber, P.G., Chou, H., Zomer, E., et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One, 8, 2013, e75361.
119. Harrison, S.A., Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis (abstr 57). November 7-11, 2014; Boston, Massachusetts. Hepatology, 60, 2014, 225A.
120. Pang, J., Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin-3 KO mice. PLoS One, 8, 2013, e57915.
121. Komers, R., Rho kinase inhibition in diabetic kidney disease. Br J Clin Pharmacol 76 (2013), 551–559.
122. Hirsova, P., Ibrahim, S.H., Krishnan, A., et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology 150 (2016), 956–967.
123. Zhou, H., Fang, C., Zhang, L., et al. Fasudil hydrochloride hydrate, a rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes. Chin Med J (Engl) 127 (2014), 225–231.
124. Peng, H., Li, Y., Wang, C., et al. ROCK1 induces endothelial-to-mesenchymal transition in glomeruli to aggravate albuminuria in diabetic nephropathy. Sci Rep, 6, 2016, 20304.
125. Baba, I., Egi, Y., Utsumi, H., et al. Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction. Mol Med Rep 12 (2015), 8010–8020.
126. Zanin-Zhorov, A., Weiss, J.M., Nyuydzefe, M.S., et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A 111 (2014), 16814–16819.
127. Zandi, S., Nakao, S., Chun, K.H., et al. ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. Cell Rep 10 (2015), 1173–1186.
128. Qu, K., Huang, Z., Lin, T., et al. New insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors: from molecular target to clinical trials. Front Pharmacol, 6, 2016, 300.
129. Fuchs, B.C., Hoshida, Y., Fujii, T., et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 59 (2014), 1577–1590.
130. Zhuang, S., Liu, N., EGFR signaling in renal fibrosis. Kidney Int(Suppl 4), 2014, 70–74.
131. Ju, W., Nair, V., Smith, S., et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med, 7, 2015, 316ra193.
132. Rintala, J.M., Savikko, J., Rintala, S.E., et al. Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis. J Nephrol 29 (2016), 359–365.
133. Chen, S., Chen, Y., Chen, B., et al. Plumbagin ameliorates CCl 4-induced hepatic fibrosis in rats via the epidermal growth factor receptor signaling pathway. Evid Based Complement Alternat Med, 2015, 2015, 645727.